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TABSTRACT
Background: The TRANSFORM (Multicenter Experience With Rapid
Deployment Edwards INTUITY Valve System for Aortic Valve Replacement)
trial (NCT01700439) evaluated the performance of the INTUITY rapid
deployment aortic valve replacement (RDAVR) system in patients with severe
aortic stenosis.
Methods: TRANSFORM was a prospective, nonrandomized, multicenter
(n ¼ 29), single-arm trial. INTUITY is comprised of a cloth-covered balloon-
expandable frame attached to a Carpentier-Edwards PERIMOUNT Magna Ease
aortic valve. Primary and effectiveness endpoints were evaluated at 1 year.
Results:Between 2012 and 2015, 839 patients underwent RDAVR.Mean agewas
73.5  8.3 years. Full sternotomy (FS) was used in 59% and minimally invasive
surgical incisions in 41%. Technical success rate was 95%. For isolated
RDAVR, mean crossclamp and cardiopulmonary bypass times for FS were
49.3  26.9 minutes and 69.2  34.7 minutes, respectively, and for minimally
invasive surgical 63.1  25.4 minutes and 84.6  33.5 minutes, respectively.
These times were favorable compared with Society of Thoracic Surgeons data-
base comparators for FS: 76.3 minutes and 104.2 minutes, respectively, and for
minimally invasive surgical, 82.9 minutes and 111.4 minutes, respectively
(P<.001). At 30 days, all-cause mortality was 0.8%; valve explant, 0.1%; throm-
boembolism, 3.5%; and major bleeding, 1.3%. In patients with isolated aortic
valve replacement, the rate of permanent pacemaker implantation was 11.9%.
At 1 year, mean effective orifice area was 1.7 cm2; mean gradient, 10.3 mm
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uCentral Message
INTUITYeliminates complete concentric annular su-
turing providing an option for rapid surgical deploy-
ment and may facilitate smaller incision surgery.Perspective
Minimally invasive aortic valve replacementmay confer
patient benefits but is underused because of technical
challenges and in part because of longer clamp times.
Likewise, ischemia is also prolonged during complex
concomitant aortic valve replacement cases. The
TRANSFORM (Surgical Treatment of Aortic Stenosis
With a Next Generation, Rapid Deployment Surgical
AorticValve) trial demonstrated that the INTUITYvalve
eliminates the need for complete concentric annular su-
turing and provides an option for rapid surgical aortic
deployment valve.From the aSwedish Heart and Vascular Institute, Structural Heart Program, Seattle,
b
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Abbreviations and Acronyms
AT ¼ as-treated
AVR ¼ aortic valve replacement
CPBT ¼ cardiopulmonary bypass time
EOA ¼ effective orifice area
LPY ¼ late patient-years
LVOT ¼ left ventricular outflow tract
NYHA ¼ New York Heart Association
OPC ¼ objective performance criteria
PVL ¼ paravalvular leak
RDAVR ¼ rapid deployment aortic valve
replacement
STS ¼ Society of Thoracic Surgeons
SVD ¼ structural valve deterioration
TRANSFORM ¼ Multicenter Experience With
Rapid Deployment Edwards
INTUITY Valve System for
Aortic Valve Replacement
XCT ¼ crossclamp time
Scanning this QR code will take
you to a video for the article.
Conclusions: INTUITY RDAVR performed effectively in
this North American trial. It may lead to a relative reduction
in aortic crossclamp time and cardiopulmonary bypass time
and has excellent hemodynamic performance. Pacemaker
implantation rate observed was somewhat greater than Eu-
ropean trials and requires further investigation. (J Thorac
Cardiovasc Surg 2016;-:1-11)
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TThe incidence and diagnosis of severe aortic stenosis has
increased as the result of the aging population and a height-
ened awareness of mortality.1 Surgical aortic valve replace-
ment has been the standard of care since the development of
prosthetic aortic valves. Numerous design modifications
have led to excellent long-term clinical outcomes.2,3
Both mechanical and tissue valves offer durable
performance, but because of concerns relating to chronic
anticoagulation, most patients currently prefer tissue
valves. Transcatheter aortic valve replacement has been
refined over the past several years, increasing treatment
choices.4-6 Recent trials have shown encouraging results
in intermediate-risk patients,7,8 and new trials currently
are planned for lower risk patient populations. In response
to the value proposition of beating-heart transcatheter2 The Journal of Thoracic and Cardiovascular Surgeraortic valve replacement, rapid deployment aortic valve
replacement (RDAVR) was developed to lessen the duration
of myocardial ischemia and cardiopulmonary bypass. To be
considered successful, however, RDAVR also must meet or
exceed attributes of conventionally implanted valves with
regard to (1) hemodynamic performance, (2) adaptability
to patient anatomy (sizes and shapes), (3) long-term
durability, and (4) absence of incremental risk. Moreover,
rapid deployment valves should facilitate aortic valve
replacement (AVR) through smaller incisions. The INTU-
ITY Valve System (Edwards Life Sciences LLC, Irvine,
Calif) relies on the same balloon-expandable deployment
system used in the SAPIEN Transcatheter Heart Valve
(Edwards Life Sciences LLC) while incorporating the
design and well-proven durability of the Carpentier-
Edwards PERIMOUNT Magna Ease Pericardial Aortic
Bioprosthesis (Edwards Life Sciences LLC).3
METHODS
The TRANSFORM (Multicenter Experience With Rapid Deployment
Edwards INTUITYValve System forAortic ValveReplacement) trial eval-
uated the performance of the new INTUITY Valve System. TRANSFORM
was a prospective, nonrandomized, multicenter, single-arm clinical trial
(ClinicalTrials.gov identifier: NCT01700439). Inclusion criteria included
subjects who were 18 years or older and required a planned AVR with or
without a concomitant procedure. Exclusion was based on preoperative
and intraoperative criteria. Preoperative exclusion criteria included, among
others, pure aortic insufficiency, emergency surgery, preexisting prosthetic
valve or ring, requirement for multiple valve surgery, hypertrophic obstruc-
tive cardiomyopathy, and the presence of a surgical aortic root aneurysm or
endocarditis (active or within 3 months of index operation). Intraoperative
exclusion criteria included anomalous coronary artery or coronary ostial po-
sition, extensive annular or root calcification, and significant calcification of
the anterior mitral leaflet or interventricular septum.
TRANSFORM was conducted by the use of Good Clinical Practices in
accordance with 21 CFR Part 812 (Investigational Device Exemption), 21
CFR Part 50 (Protection of Human Subjects), CFR Part 54 (Financial
Disclosure by Clinical Investigators), 21 CFR Part 56 (Institutional Review
Boards), and the Health and Insurance Portability and Accountability Act.
The clinical protocol, consent form, and protocol amendments were
approved by an institutional review board or ethics committee at each
investigational site.
INTUITY Valve System
The INTUITY Valve System (Figure 1, A) is a Carpentier-Edwards
PERIMOUNT Magna Ease Pericardial Aortic Bioprosthesis (Model
3300TFX) modified with an attached precrimped, cloth-covered
balloon-expandable stainless-steel frame. The delivery system is composed
of a malleable tubular handle into which an integrated balloon catheter is
inserted. After the prosthesis is positioned, the balloon expands the valve
frame (Figure 1, B) within the left ventricular outflow tract (LVOT),
establishing a seal between the aortic annulus and the frame. The stented tri-
leaflet valve is composed of glutaraldehyde-preserved bovine pericardium
mounted on a flexible cobalt chromium wire form. The outer frame is
covered with woven PTFE, and the annulus frame is covered with polyeth-
ylene terephthalate. Thevalve is available in sizes 19, 21, 23, 25, and 27mm.
Operative Procedure
The following steps were used to deploy the INTUITY Valve System.
Three equidistant guide sutures were placed in the nadir of the annulusy c- 2016
FIGURE 1. Edwards INTUITY aortic valve. A, Valve before deployment; B, after deployment.
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Tand through the sewing cuff of the valve implant. The guide sutures
facilitated lowering the INTUITY valve and seating it on the annulus.
The holder/expansion device was attached to the valve. After the balloon
catheter was inserted through the valve, it was inflated to a prespecified
pressure based on valve size. This expanded the frame and secured the
valve within the annulus and LVOT. After proper valve seating was
verified, the guide sutures were tied and cut. Device technical success
was defined as successful implantation of the INTUITY valve within 2
attempts. If a second implant attempt failed, no additional attempts were
permitted per protocol, and a conventional surgical valve was used.
Video 1 shows an aortic valve replacement with implantation of the INTU-
ITY valve, showing the unique features of this rapid deployment system via
an upper mini-sternotomy approach.
Statistical Methods
Statistical analysis was completed with SAS version 7 (SAS Institute,
Inc, Raleigh, NC). Adjudication of adverse events was conducted by an in-
dependent Clinical Events Committee and trial safety was monitored by a
Data Monitoring Committee. Trial endpoints were based on definitions
published in the Guidelines for Reporting Mortality and Morbidity after
Cardiac Valve Interventions by Akins et al.9 Primary safety endpoints
were thromboembolism, valve thrombosis, paravalvular leak (PVL),
bleeding events, and endocarditis. The objective performance criteria
(OPC) major PVL is an endpoint expressly required by the US Food and
Drug Administration for valve approval. Because it is clinically defined,
it could underreport PVL discovered on echocardiography in the absence
of signs or symptoms. Accordingly, the rates of echocardiography core
laboratory-adjudicated PVL (0/1þ/2þ/3þ/4þ) also are reported. Primary
effectiveness endpoints were New York Heart Association (NYHA)
functional class, effective orifice area (EOA), and mean pressure gradient.VIDEO 1. Surgical upper mini-sternotomy aortic valve replacement im-
plantation of the INTUITY valve, demonstrating the unique features of
this rapid deployment system.
The Journal of Thoracic and CSecondary safety endpoints were mortality, reoperation, nonstructural
valve dysfunction, structural valve deterioration (SVD), device-related
conduction defects, and significantly abnormal laboratory values. Second-
ary effectiveness endpoints were device technical success, procedural suc-
cess, cardiopulmonary bypass time (CPBT), crossclamp time (XCT),
quality of life (SF-12v2 Survey), peak pressure gradient, and EOA index.
Trial safety outcomes are reported as early (30 postoperative day) or
late (>30 postoperative day) events. The linearized rate is the number of
late events divided by the total late patient-years (LPYs) number as 95%
upper confidence intervals. One-year Kaplan-Meier estimates were
computed on all primary and secondary safety outcomes. Echocardio-
graphic studies were evaluated by a central echocardiographic core lab.
PVLwas defined as per Valve Academic Research Consortium-2 criteria.10RESULTS
Between September 2012 and December 2015, 889
patients were enrolled at 29 investigational sites. Among
patients enrolled, 839 were implanted with the INTUITY
Valve System. Follow-up was 96.3% complete at 1 year
(Figure 2) and included 912.2 patient-years and 844.5 LPY.Demographics and Baseline Characteristics
Mean age was 73.5  8.3 years, with 24.6% being
80 years or older and 64.5% male. Thirty-two percent
(270 of 836) presented with NYHA Class III or IV
symptoms. Baseline characteristics and cardiovascular
comorbidities are listed in Appendices E1-E3. More thanFIGURE 2. Patient flowchart and follow-up.
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TABLE 2. Valve model and size distribution (as-treated INTUITY,
n ¼ 839)
Valve size
Valve model
All modelsGen I Gen II
19 mm 10.1% (11/109) 5.2% (38/730) 5.8% (49/839)
21 mm 27.5% (30/109) 19.5% (142/730) 20.5% (172/839)
23 mm 30.3% (33/109) 33.2% (242/730) 32.8% (275/839)
25 mm 25.7% (28/109) 29.7% (217/730) 29.2% (245/839)
27 mm 6.4% (7/109) 12.5% (91/730) 11.7% (98/839)
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T25% had important noncardiac conditions that included
smoking (58.0%), obesity (46.7%), diabetes (33.1%),
and cancer (30.0%). Two thirds of patients (559 of 839)
had preoperative conduction abnormalities.
Operative Data
The as-treated (AT) surgical approach and procedure
performed are listed in Table 1. For all enrolled patients
(intent to treat), 62% underwent isolated AVR (524 of
839). Of those who had isolated AVR, full sternotomy
(FS) was performed in 40% (221 of 548), and a minimally
invasive incision was used in 60% (327 of 548). The valve
generation and size distribution are listed in Table 2. Device
technical success (ie, successful implant of INTUITY
within 2 attempts) was achieved in 839 of 889 (94.4%)
patients. Of 839 successful implants, 773 (92%) were
achieved on the first attempt and 66 (7.9%) on the second.
Conversion to a nontrial valve because of implant failure
occurred in 5.5% of patients (49 of 888).
For isolated RDAVR in all enrolled patients, mean XCT
and CPBT for FS were 49.3  26.9 minutes and
69.2  34.7 minutes, respectively, and for minimally inva-
sive surgery 63.1  25.4 minutes and 84.6  33.5 minutes,
respectively. These times were favorable compared with
Society of Thoracic Surgeons (STS) database comparators
for FS: 76.3 minutes and 104.2 minutes, respectively, and
for minimally invasive surgery, 82.9 minutes and 111.4 mi-
nutes, respectively (P<.001). XCT and CPBT stratified by
procedure and surgical approach are listed in Appendices
E4 and E5 with comparisons to unadjusted summary
statistics from the STS Adult Cardiac Surgery Database.TABLE 1. Surgical approach and procedure (as-treated INTUITY,
n ¼ 839)
Approaches and procedures % (n/N*)
Approach
Full sternotomy 59.0 (495/839)
Upper mini-sternotomy 32.8 (275/839)
Right anterior thoracotomy 8.2 (69/839)
Procedure
Isolated AVR 62.5 (524/839)
AVR þ CABG 24.9 (209/839)
AVR þ CABG þ other 3.6 (30/839)
CABG 28.5 (239/839)
1 graft 12.0 (101/839)
2 grafts 10.1 (85/839)
3 grafts 4.6 (39/839)
4þ grafts 1.1 (9/839)
Unknown 0.6 (5/839)
Atrial ablation 5.5 (46/839)
Atrial septal defect repair 1.3 (11/839)
Aortic aneurysm/dissection repair 0.1 (1/839)
Other concomitant procedure 9.9 (83/839)
AVR, Aortic valve replacement; CABG, coronary artery bypass grafting. *N is the
number of patients with available operative data. Subjects could have more than
one concomitant procedure.
4 The Journal of Thoracic and Cardiovascular SurgerTrial Safety Outcomes
Intent-to-treat all-cause early mortality was 0.9%
(8/889) and 3.8% (34/889) at 1 year. The remaining safety
outcomes are presented AT. Early all-cause AT mortality
was reported in 7 patients (0.8%; 7/839); 6 died before
hospital discharge. Four of the 7 deaths were adjudicated
by the Clinical Events Committee as potentially both car-
diovascular and valve-related (0.5%; 4/839); these included
perioperative bleeding, gastrointestinal catastrophe,
heparin-induced thrombocytopenia, and unexplained on
day 26. Cardiovascular only-adjudicated deaths (n ¼ 2)
were caused by stroke and gastrointestinal catastrophe.
An early multiorgan failure death was adjudicated as
neither cardiovascular nor valve related. Mortality in pa-
tients requiring 2 attempts at implant was 1.2% (1/82).
Late all-cause mortality was reported in 25 patients
(3.0% per LPY). Eight of the 25 deaths were adjudicated
to potentially valve-related (1.1% per LPY) without a
known cause of death and of these, 5 were also adjudicated
as cardiovascular. At 1 year, Kaplan-Meier freedom from
all-cause mortality was 96.4% (Figure 3).
Table 3 lists the early and late event rates and 1 year
Kaplan-Meier estimates for primary safety endpoints.
These are depicted graphically in Figure 4. Major bleeding
was reported in 28 patients that included 11 early (1.3%,
11 of 839) and 21 late events (2.5% per LPY). Only 1
late major bleeding event was adjudicated as valve-
related (0.1% per LPY). Most bleeding events resolved
without clinical sequelae and occurred while the subjects
were receiving anticoagulant treatment either for a
concomitant condition or when recommended to reduce
the risk of thromboembolism.
Moderate and severe OPC PVL was observed in 1.2%
and 0.4%, respectively. Major OPC PVL, defined as PVL
of any severity that led to a therapeutic intervention or
caused a serious adverse event,9 was reported in 9 pa-
tients. Two occurred early (0.2%, 2 of 839) and 7 late
(0.8% per LPY). Two patients were reoperated on within
30 days of the index operation and 7 patients on postop-
erative days 102, 126, 140, 412, 413, 442, and 712.
Freedom from major OPC PVL was 99.3%. Two cases
of late hemolysis and no cases of endocarditis were
reported.y c- 2016
FIGURE 3. Kaplan-Meier freedom from all-cause mortality.
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TTable 4 shows early and late event rates and 1-year
Kaplan-Meier estimates for all-cause mortality, reopera-
tions, device-related conduction defects, nonstructural
valve dysfunction, and SVD. Ten reinterventions (5 percu-
taneous repairs and 5 surgical explants) of the INTUITY
were performed in 9 subjects. Explants occurred early in
1 (0.1%, 1 of 839) and late in 4 (0.5% per LPY) patients.
All reoperations were performed for aortic regurgitation.
At 1 year, Kaplan-Meier freedom from reintervention was
99.3%.
Echocardiographic PVL as assessed by the core
laboratory at 1 year was 1þ (trivial or none) in 91.5%
(475/519), 2þ (mild) in 6.9% (36/519), 3þ (moderate) in
1.2% (6/519), and 4þ (severe) in 0.4% (2/519). New per-
manent pacemaker implantation was required during index
hospitalization in 11.9% (57 of 481) of patients undergoing
isolated AVR. Of those patients having postoperative
pacemaker implant, 73.3% had preexisting complete right
bundle branch block and 19.65% had preexisting sinus
bradycardia. No cases of SVD were reported.
Trial Effectiveness Outcomes
At 1 year, 77.1% (421 of 549) of patients were in NYHA
Class I, 19.6% (107 of 546) in NYHAClass II, 2.7% (15 ofTABLE 3. Primary safety endpoints: As-treated analysis
Adverse event or outcome
Early events
N n, m, n/N
Thromboembolism 839 29, 29 (3.5)
Valve thrombosis 839 0, 0 (0.0)
Endocarditis 839 0, 0 (0.0)
All bleeding 839 13, 13 (1.5)
Major bleed 839 11, 11 (1.3)
All PVL 839 9, 9 (1.1)
Major PVL 839 2, 2 (0.2)
n, Number patients; m, number of events; LPY, late patient-years; UCL, upper confidence
The Journal of Thoracic and C546) in NYHA Class III, and 0.5% (3 of 546) in NYHA
Class IV. Overall, NYHA Class improved in 73.1% (399
of 546), remained unchanged in 23.6% (129 of 456), and
became worse in 3.3% (18 of 546). INTUITY valve hemo-
dynamic data (EOA and mean gradient) are listed in
Table 5. Health-related quality of life was assessed using
the Short Form-12v2. At 1 year, significant improvement
was observed compared with baseline in both physical
health (41.8  10.2 to 47.6  9.7, P<.0001) and mental
health dimensions (51.3  9.9 to 54.3  8.6, P<.0001).DISCUSSION
The TRANSFORM trial evaluated the performance of
the new INTUITY Valve System, which was designed for
RDAVR in patients with severe aortic stenosis. TRANS-
FORM was a prospective, nonrandomized, multicenter,
single-arm clinical trial. The INTUITY Valve System com-
bines the well-proven Carpentier-Edwards PERIMOUNT
Magna Ease Pericardial Aortic Bioprosthesis with a
cloth-covered balloon-expandable stainless-steel frame. Pa-
tients had a mean age of 73.5 years, 24.6% were 80 years
and older, and they had a mean STS predicted risk of mor-
tality of 2.5% and logistic EuroSCORE II of 3.3%, which
were consistent with low operative risk. FS was used
in 40% and upper mini-sternotomy or right anterior
thoracotomy in 60%; both approaches were associated
with a technical success rate of 95%.
In this study, minimally invasive incisions were used
twice as frequently as the 20% observed rate in the large,
multicenter registry of the German Society for Thoracic
and Cardiovascular Surgery.11 The mean XCT and CPBT
for FS and upper mini-sternotomy/right anterior thoracot-
omy compared favorably with STS Adult Cardiac Surgery
Database comparators. The rate of surgical complications
at 30 days was exceptionally low, with all-cause mortality,
0.8% (7 of 839); reoperation, 0.2% (2 of 839); valve
explant, 0.1% (1 of 839); thromboembolism, 3.5% (29 of
839); and major bleeding, 1.3% (11 of 839). The rate of
major PVLwas 0.2% (2 of 839). The rate of new permanent
pacemaker implantation was 11.9%. At 1 year, most
patients had improved symptomatically, with 77.2% (424Late events Freedom from event
(SE) at 1 yn, m,%/LPY 95% UCL
22, 22 (2.6) 3.7 0.939 (0.009)
0, 0 (0.0) 0.2 1.000 (0.000)
0, 0 (0.0) 0.2 1.000 (0.000)
37, 43 (5.1) 6.5 0.941 (0.009)
19, 21 (2.5) 3.5 0.962 (0.007)
15, 15 (1.8) 2.7 0.977 (0.005)
7, 7 (0.8) 1.5 0.993 (0.003)
limit; SE, standard error; PVL, paravalvular leak.
ardiovascular Surgery c Volume-, Number- 5
FIGURE 4. Kaplan-Meier Freedom from thromboembolism (A), bleeding (B), PVL (C), Major PVL (D).
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Tof 549) in NYHAClass I, and 19.5% (107 of 549) in NYHA
Class II. Valve hemodynamic performance was excellent at
1 year, with an overall mean EOA of 1.7 cm2 and mean
gradient of 10.3 mm Hg. Taken in the aggregate, these
data demonstrate excellent performance profiles of the IN-
TUITY Valve System.
Prolonged XCTs correlate with worse clinical outcomes,
but the relationship is complicated and difficult to resolve
statistically. In studies that applied unadjusted analysis,
longer XCT was associated with increased operative
mortality and morbidity. In report of Nissinen and
colleagues12 on 3280 patients undergoing a variety ofTABLE 4. Secondary endpoints: As treated
Outcome 30 d
Freedom from
event at 1 y (SE)
All-cause mortality 0.8% (7 of 839) 0.964 (0.007)
Valve-related mortality 0.5% (4 of 839) 0.985 (0.005)
Reoperation 0.2% (2 of 839) 0.993 (0.003)
Valve explant 0.1% (1 of 839) 0.996 (0.002)
Stroke 2.6% (22 of 839)
Valve thrombosis 0.0% 1.000 (0.000)
SE, Standard error.
6 The Journal of Thoracic and Cardiovascular Surgercardiac operations, the receiver operating characteristic of
30-minute increments of XCT revealed that the area under
the curve was significantly correlated with all-cause mortal-
ity and stroke at 30 days. Moreover, the authors proposed a
critical threshold value for XCT of 150 minutes, where
observed mortality was 1.8% versus 12.2% (odds ratio
8.78, 95% confidence interval 4.64-16.61); however,
numerous confounding factors account for increases in
both XCT and operative mortality, such as high predicted
operative risk, technical complexity, and intraoperative
complications.
For example, Doenst and colleagues13 studied 27,215 pa-
tients undergoing cardiac operations stratified by preopera-
tive left ventricular ejection fraction. Multivariate
regression analysis revealed that XCT was an independent
predictor of mortality for patients with a left ventricular
ejection fraction greater than 40% (odds ratio 1.01 per min-
ute of XCT, 95% confidence interval 1.01-1.02) but not for
patients less than 40%. The authors attributed this to the
high mortality rate observed in patients with extremely
short XCTs (ie, 30 minutes or less). Nonetheless, other in-
vestigators have reported an independent association be-
tween XCT and operative mortality and morbidity.14,15y c- 2016
TABLE 5. Primary effectiveness endpoints (EOA, mean gradients) at 1 year
EOA and mean gradients at 1 y
19 mm, n mean
(min, max)
21 mm, n mean
(min, max)
23 mm, n mean
(min, max)
25 mm, n mean
(min, max)
27 mm, n mean
(min, max)
Total, n mean
(min, max)
EOA, cm2 36, 1.1  0.1
(1.0, 1.3)
113, 1.3  0.1
(1.0, 1.8)
157, 1.7  0.2
(1.2, 2.1)
127, 1.9  0.2
(1.4, 2.9)
58,
2.2 0.2
(1.3, 2.5)
491, 1.7  0.3
(1.0, 2.9)
Mean gradient, mm Hg 36, 13.9  3.9
(7.2, 25.1)
15, 11.6  3.6
(5.5, 23.5)
165, 10.4  3.5
(3.6, 24.6)
132, 9.1  3.2
(3.1, 19.6)
61, 8.3  3.7
(3.6, 28.7)
509, 10.3  3.8
(3.1, 28.7)
EOA, Effective orifice area.
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TThe INTUITY Valve System has been associated with a
reduction in XCT and CPBT. In a recently published ran-
domized controlled trial, Borger and colleagues16 reported
that INTUITY (n ¼ 46) led to a 24% reduction in XCT
compared with a group treated with a conventionally im-
planted bioprosthesis (n ¼ 48; 41.3  20.3 minutes vs
54.0  20.3, P<.001). The current study generalizes this
finding to a larger surgeon cohort by demonstrating that IN-
TUITY was associated with lower XCTs and CPBTs
compared with unadjusted summary statistics reported in
the STS Database. Moreover, if the causal relationship be-
tween XCT and adverse events becomes stronger as the
XCT exceeds some critical value, then it may be reasonable
to assume the benefit of INTUITY will be greater as the de-
gree of surgical complexity rises. Hence, as more patients
are referred for AVR plus coronary bypass grafting, or
tricuspid valve surgery, or atrial fibrillation surgery, the
value proposition of the INTUITY Valve System may be
more compelling. Compared with the STS Database,
INTUITY was associated with clinically meaningful reduc-
tions in mean XCT in patients undergoing AVR plus coro-
nary bypass grafting 31, 2, or 3.
The INTUITY Valve System performed effectively with
clinically acceptable rates of PVL. In the TRANSFORM
trial, a central echocardiographic core laboratory was
used to evaluate all echocardiographic studies. At 1 year,
the rate of moderate and severe PVLs was 1.2% (6 of
519) and 0.4% (2 of 519). This result compares favorably
with clinically overt PVL rates reported in the literature
for surgical AVR.17-21
In the current study, the overall rate of new permanent
pacemaker implantation in patients with isolated AVR
was 11.9% (57 of 481); the rates reported in the surgical
literature range between 3.0% and 11.8%.22 The current
implantation rate is in contrast to the observed rate of
approximately 5% as reported in the European INTUITY
studies for isolated AVR, whereas the remaining endpoints
were similar overall.16 This may be related to the high prev-
alence (roughly two-thirds) of preoperative conduction ab-
normalities observed in the current study. Among 342
patients undergoing isolated AVR, Dawkins and col-
leagues23 reported preoperative atrial fibrillation in 12%,
left anterior hemi block in 10%, left bundle branch blockThe Journal of Thoracic and Cin 7%, and right bundle branch block in 5%. Moreover,
they observed that patients with preoperative conduction
abnormalities were significantly more likely to require a
new permanent pacemaker compared with those without,
16% versus 6% (P ¼ .004). Likewise, in sutureless valves,
a greater rate of pacemaker implantation (11-fold) has been
observed in the presence of preoperative right bundle
branch block.24 Whether INTUITY’s balloon-expandable
frame imparts greater radial force within the LVOT
compared with a conventional valve and, therefore, predis-
poses to a greater likelihood of pacemaker implantation in
patients with baseline conduction abnormalities warrants
additional study.
The INTUITY Valve System leverages the well-proven
hemodynamic performance and durability of the
Carpentier-Edwards PERIMOUNTMagna Ease Pericardial
Aortic Bioprosthesis. Recently, Johnston and colleagues25
reported on 12,569 patients who underwent AVR with the
PERIMOUNT valve at the Cleveland Clinic during a
27.5-year period. In patients younger than 60 years, the
Kaplan-Meier estimates for SVD at 10 and 20 years were
5.6% and 45%, respectively, and, in patients 60 to 80 years
old, a remarkable 1.5% and 8.1%, respectively. Unlike
conventional surgical valves, the presence of a balloon-
expandable stainless-steel frame within the LVOT may pro-
mote circularity and create ideal flow characteristics at the
valve inlet. This unique design feature of the INTUITY
Valve System may lessen the risk of prosthesis-patient
mismatch, particularly in those patients with a small aortic
root.26
Study Limitations
The TRANSFORM trial was a single-arm study without
an active comparator group. Thus, it is susceptible to selec-
tion and channeling biases. Because ‘‘roll-in’’ cases were
not excluded, the reported outcomes reflect the potentially
negative impact of the surgeons’ learning curve. During
the enrollment phase of the study, considerable emphasis
was placed on procedural training and the sharing of best
practices among the investigators. Nonetheless, the possi-
bility of performance bias cannot be excluded. The clinical
endpoints were objectively defined a priori, and the out-
comes were determined independently by a Clinical Eventsardiovascular Surgery c Volume-, Number- 7
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TCommittee and an echocardiographic core laboratory. Thus,
potential detection and measurement biases were mitigated
but not completely eliminated. The current report is limited
to trial safety and effectiveness at 1 year, with 912.2 patient-
years follow-up. Hence, additional follow-up is required to
establish long-term safety and effectiveness. The study did
not standardize intraoperative valve evaluation for core lab-
oratory review, which limits our ability to compare with
subsequent formal valve evaluations and could potentially
account for unappreciated significant PVL in the OR. In
addition, our normative comparison was to the STS
database. Although not a ‘‘matched’’ comparison, it is the
only dataset available and provides insight to the current
practice of AVR by the greatest proportion of US surgeons;
the possibility exists that the trial surgeons were more
experienced with aortic valve surgery and that the
lower operating room times observed were affected by
this fact.
CONCLUSIONS
The INTUITY RDAVR system performed effectively in
this North American trial. This system has excellent hemo-
dynamic performance, and it potentially reduces aortic
XCT and CPBT while facilitating minimally invasive ap-
proaches for surgical AVR. This may confer benefits to
the patient, such as decreased mortality and morbidity,
reduced length of intensive care unit and total hospital
stay, and increased patient satisfaction. By leveraging the
well-proven hemodynamic performance and durability of
the Carpentier-Edwards PERIMOUNT Magna Ease Peri-
cardial Aortic Bioprosthesis, the INTUITY Valve System
is expected to have similar hemodynamic characteristics
and long-term durability and performance. Overall pace-
maker implantation rate observed, although in the range
of the reported literature, was greater than in INTUITY Eu-
ropean trials and will require further investigation.
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TDiscussion
Dr P. Kappetein (Rotterdam, The
Netherlands). Mr Chairman, ladies
and gentlemen. Thank you for inviting
me to discuss this paper, and I have
to congratulate Dr Chitwood and
colleagues on performing a trial on a
new surgical device for aortic valve
replacement. This by itself is great
news, as in recent years much of the investments of the
valve companies were focused on transcatheter heart
valves. Sutureless heart valves have the potential to make
valve implantation easier and faster. At the same time,
they need to offer the same hemodynamic performance,
adaptability to patient anatomy, no increase in adverse
events, and offer the same long durability as standard
surgical heart valves.
I had the advantage of having read the article, and in the
introduction section you write that sutureless heart valves
were developed to lessen the duration of myocardial
ischemia and cardiopulmonary bypass time. However, if
lessening the duration of myocardial ischemia and bypass
time is so important that it justifies the implantation of a
new device without a proven track record of durability
and a price that at least is twice as high as a standard surgical
bioprosthesis, I am surprised that we perform a minimally
invasive procedure with 14-minute longer crossclamp
time and 16-minute longer cardiopulmonary bypass time
compared with a full sternotomy.
So the first question to you: is a reduction in crossclamp
time really that important? Does the reduction in operative
time also justify the greater price of the device? And if we
want to do a minimally invasive procedure, can we notThe Journal of Thoracic and Cachieve the same reduction in time by using a Cor-Knot
suture?
Dr Chitwood. Thank you very much,
Dr Kappetein, for your comments.
Clearly, minimally invasive operations
take longer, no matter who is doing
the operation. Both the minimally inva-
sive anterior thoracotomy and a hemi-
sternotomy approach take longer than
a full sternotomy operation. I think
any reduction in cross clamp time is important. In theardiovascular SurTRANSFORM trial, the times that were reduced were
significantly both for the full sternotomy operations as
well as for minimally invasive procedures.
Can I tell you whether a reduction in 20 minutes makes
any difference in long-term survivability? No, I can’t. In pa-
tients with concomitant operations who required multiple
bypasses, however, we showed that the significant reduction
in time was significant and most likely important.
Moreover, this time is important especially if multiple valve
procedure or other combination operations were done. The
reduction in cardiopulmonary bypass and crossclamp times
should be very beneficial when you are doing a 4-vessel cor-
onary bypass operation, possibly a Maze procedure, all
combined with an aortic valve replacement.
As far as theprice, it has not beendeterminedwhat theprice
will be, and we are hoping that Centers for Medicare and
Medicaid Services in the United States will give us an add-
on that will provide extra reimbursement for this device.
Clearly, the price of any of the advanced valves, whether
transcatheter aortic valve replacement or anyof theminimally
invasive rapid deployment valves, is going to be an issue.
Dr Kappetein.With the Cor-Knot device, could you not
achieve the same result?
Dr Chitwood. This device is a time-saving secret,
because the Cor-Knot device does decrease in aortic and
mitral valve implantation times. It does add about $800
per operation. There is doubt that will ever be a randomized
study evaluating a rapid deployment valve versus a surgical
valve deployed with the Cor-Knot device. Definitely, the
Cor-Knot device is an enabling technology.
Dr Kappetein. Thank you. My next question is thus: the
total of permanent pacemaker implants is 14%, which is
much greater than one would expect. The paper by Vinod
Thourani, ‘‘Contemporary Real-World Outcomes of
Surgical Aortic Valve Replacement in 141,905 Low-Risk,
Intermediate-Risk, and High-Risk Patients,’’ published in
the Annals last year, showed that the incidence of heart
block was only 4%. In most other series, the incidence of
postoperative pacemaker varies between 2% and 7%.
In the Methods section, you describe that the trial end-
points were based on definitions published in the guidelines
for reporting mortality and morbidity after cardiac valve
intervention by Akins et al. In the current study, however,gery c Volume-, Number- 9
Evolving Technology Barnhart et al
E
Ta completely new concept was introduced of valve-related
and nonvalve-related pacemaker implantation. This is not
described in the Akins paper, nor in the Valve Academic
Research Consortium-2 definitions. By this new concept,
the pacemaker rate decreases immediately from 14% to
1.3%, which all of a sudden is much lower than any other
previously published series.
Although everyone knows from the transcatheter valve
studies that the radial force of transcatheter aortic valve
replacement devices is responsible for a greater pacemaker
rate and that with greater radial force the pacemaker rate is
increased, do you really think that the valve is not respon-
sible for the greater pacemaker rate and should you not
revisit your definition?
Dr Chitwood.Well, I think you noticed in the presenta-
tion that I only used the raw pacemaker insertion data. I
didn’t use any other objective performance criteria type of
variation.
When we went back and looked at all the INTUITY
studies in Europe, the pacemaker rate was 5.8% versus
14% in the TRANSFORM trial. Then we went back and
looked at the preoperative electrocardiograms for any
type of dysrhythmia, we found a very high level, with
45% having a right bundle block. So we need to do a
deep dive to look at why the European data were different.
In the Perceval valve study done by Laborde and colleagues,
the pacemaker rate was around 11%.
Any valve that has a skirt below the annulus has a risk of
creating radial pressure on the atrioventricular (AV) node or
bundle. I agree pacemaker implantation rates are always a
concern. When a recent meta-analysis looked at pacemaker
insertion rates after a traditional surgical valve implanta-
tion, the incidence was about 7%; therefore, there is clearly
morework to be done in this area with more investigation of
the data, and we are doing this at present.
Dr Kappetein. The last point is the conversion to a stan-
dard prosthesis due to implant failure, which occurred in
5.5% of patients. Did this occur after the valve container
already was opened, which means that the cost will even be
greater, or can one already knowbeforehand that implantation
of the valve is not possible as soon as the aorta is opened?
Dr Chitwood. This is related to both situations. Most of
these, more than 60%, were from either a sizing or a seating
problem and in 10% there were pop-ups after implantation.
Basically the valve was seated and it popped back up, with
the surgeon not feeling comfortable continuing with a third
implantation. Surgeons were allowed at least 2 attempts at
implantation. Therefore, most of these pop-ups were from
difficult sizing.
We think thatwe have solved the sizing problem, because in
the European group we found that sizing was a bit better. We
determined that when one downsizes the valve greater than
2 mm there clearly are more paravalvular leaks. In contradis-
tinction, if you upsize toomuch, then onemay have problems10 The Journal of Thoracic and Cardiovascular Surgewith pop-ups. Therefore, right sizing is the key, and we now
have better information of how to do that correctly.
DrKappetein.Congratulations on a great study and with
excellent results, and thank you for the privilege.
Dr H. Najm (Cleveland, Ohio). I en-
joyed your presentation. My question
is relevant to the anatomy of the aortic
root and suitability of this valve to it,
and it also properly relates to the 49 pa-
tients who were disqualified from this
valve. Would this valve be suitable for
those patients with a small or calcified
sinutubular (ST) junction, because I know it is difficult tory c- 2016negotiate that skirt through a smaller ascending aorta, and
the other question is would the bicuspid aortic valves be
suitable for this and could you have had lower rates of para-
valvular leaks if they were only implanted in tricuspid aortic
valves as opposed to bicuspid aortic valves?
Dr Chitwood. I will answer the last question first. We did
not find that there was a difference in implanting in the
presence of bicuspid aortic valves as far as leaks. Also,
the narrow ST junction can be a problem, especially when
it is calcified. Surgeons in this study used different aortoto-
mies; each surgeon could use the aortotomy that he nor-
mally used. Unless the ST junction is calcified totally, one
can cut across the ST junction with a hockey stick–shaped
incision. There didn’t seem to be a problem seating in
that circumstance; however, when you have a highly calci-
fied ST junction or mitral valve anterior leaflet calcium,
seating really becomes a problem.
Dr Najm. Would you do it in a double-valve re-
placement?
DrChitwood. I would.We did not include this parameter
in the study, but I certainly would in combination with a
mitral valve repair. The skirt is short enough that if you
did a mitral valve replacement combined with an INTUITY
aortic valve replacement, I think it would work fine.
Dr A. El Gamel (Hamilton, New Zea-
land). Using some of these valves, how
much decalcification do you need? Do
you do complete decalcification as
surgical? And also do you check under
the valve with a telescope or a mirror
after deployment that the valve is intact
with the ring?Dr Chitwood. Early on, we thought it would be like a
SAPIEN-type valve in that you would do less debridement.
The notion then was to leave some calcium so that the valve
would hang in place. We found that as we moved ahead with
this study that a standard surgical debridement was best, and
so we did not leave excess calcium.
In answer to your question about using an endoscope to
confirm seating, I like cameras. I do a lot of photography,
and I started out doing this. It was not part of the protocol.
Barnhart et al Evolving TechnologyActually, Michael Borger started doing this in Leipzig a
long time ago. He would pass a 5-mm endoscope camera
below the annulus to see if the valve was really seated
well. However, most of our investigators did not use a
scope. It was not part of the protocol, and it did not seem
to make any difference in results.
Dr El Gamel. Is there a learning curve number?
Dr Chitwood. There is a learning curve for everything.
Yes, there is a learning curve, but it relates to sizing. We
basically found that when we did a really deep dive on
how to best size these, we did decrease the learning curve.
At first we were not debriding as much as we did later. So
there was a minimal learning curve, and we modified our
technique as we moved ahead.
Dr S. Damle (Lincoln, Neb).
Regarding the 5% of patients in
whom this valve couldn’t be placed,
was there a consequence such as longer
bypass time, conversion to sternotomy,
et cetera?E
TDr Chitwood. The 5.8% of patients, the 49 patients?
Dr Damle. Yes, the 49 patients in whom trouble seating
the valve led to a conversion to a regular valve, likely longer
crossclamp time, were there any consequences in the
30 days or one year for those patients?
Dr Chitwood. No, not in survival or complications, and it
did not result in more conversions from a mini-thoracotomy
to a full sternotomy. Most of these were related to a
seating problem. I don’t have the data, but you would
expect that if one tried two attempts that this timewould ablate
some of the benefit of having a shorter cross clamp time. So I
would expect those timeswould be just a bit longer.Wedid not
see any adverse effects in those patients. We cautioned
surgeons about continuing to work with this valve if they
felt it couldn’t be implanted. Then they should switch to a
conventional surgical valve implantation.
Dr T. Rosengart (Houston, Tex). Ease
of use is an important component of
any valve quality profile. In this case,
ease of use may encourage increased
adoption of minimally invasive ap-
proaches, which would be advantaged
by facilitated valve implantation tech-
niques. Dr Chitwood, do you agree
that that’s an important component of this valve, and if
so, how do you incorporate that ultimately into the adoption
process?
Dr Chitwood. Well, I think type of valve will enhance
the adoption of less invasive techniques. We thought a num-
ber of years ago that if we could have some sort of rapid
deployment device there would be a benefit for minimallyThe Journal of Thoracic and Cinvasive operations, because we knew that a standard
minimally invasive aortic valve replacement, especially
through a mini-thoracotomy, would take significantly
longer than through a full sternotomy. Therefore, both
shortening the crossclamp time and easing deployment
are very important, especially when you are operating
through a very small incision. Therefore, this type of
prosthesis could enhance the adoption of minimally
invasive techniques.
My belief is everything is going towardminimally invasive
techniques if possible. We will have to see if this happens.
Dr C. Muneretto (Brescia, Italy).
Congratulations, Dr Chitwood. I en-
joyed very much your presentation.
As far as the incidence of AV block is
concerned, you pointed out that in
your study AV block was significantly
more frequent compared with the
European experience. It is well known
that AV block may not only be related to the valve designardiovascular Surgbut may be also related to the surgical technique, as, for
example, the deepness of the device driving suture, rapid
deployment device oversizing, and incomplete annular
calcification removal.
On the basis of the high incidence of AV block in your
experience, do you plan to re-evaluate some aspects of
your surgical techniques?
Dr Chitwood. No, we really didn’t. Everyone used their
own technique, but clearly the skirt positioned below the
annulus could have something to do with block. The thing
that really confounds me is why are these results different
than our European studies using the same valve? Why are we
different? Maybe Europeans don’t have as high an incidence
of right bundle branch block, but I don’t think that is the
case. So we are going back and looking at this issue in detail.
Dr M. Shrestha (Hannover, Ger-
many). Just a small comment. I had
the honor of doing the first-in-human
implantation way back in 2010 in
Hannover.What we have seen is I agree
with Randy Chitwood. I just wanted to
answer to Pieter that it is not fair to
compare the results of this ID trial
with the established valves, because there is a learning
curve, and we saw that in Hannover that after you have
gone through a learning curve, afterwards that it is really
good. So that more people can do minimally invasive aortic
valve replacement and especially in combined cases with
four coronaries and aortic valve replacement, it does bring
down the cross clamp time and the mortality.
Dr Chitwood. Dr Shrestha has used all types of these
rapid deployment valves, so he should know. Awesome.
Thank you.ery c Volume-, Number- 11
APPENDIX E1. Baseline patient characteristics (as-treated
INTUITY, n ¼ 839)
Characteristic
Age, y, N, mean  SD (min-max) 839: 73.5  8.3 (34-95)
Sex % (n/N)
Female 35.5 (298/839)
Male 64.5 (541/839)
NYHA classification % (n/N)
Class I 15.6 (130/836)
Class II 52.2 (436/836)
Class III 30.5 (255/836)
Class IV 1.8 (15/836)
Risk scores, n, mean  SD (min-max)
STS risk of mortality (%) 733: 2.5  1.8 (0.4-14.6)
EuroSCORE II (%) 839: 3.3  3.4 (0.5-31.6)
Etiology % (n/N)
Degenerative 91.5 (768/839)
Rheumatic 0.7 (6/839)
Remote endocarditis 0.0 (0/839)
Other etiology 8.0 (67/839)
Diagnosis for replacement % (n/N)
Stenosis 68.9 (578/839)
Stenosis with insufficiency 31.1 (261/839)
Intervention % (n/N)
Percutaneous coronary intervention 16.8 (141/839)
CABG 6.6 (55/838)
Permanent pacemaker or ICD 6.2 (52/839)
Carotid artery intervention 4.2 (35/839)
Limb artery intervention 2.3 (19/839)
Abdominal aorta intervention 1.0 (8/839)
Aortic valve valvuloplasty 0.4 (3/839)
Mitral valve valvuloplasty 0.0 (0/839)
Tricuspid valve valvuloplasty 0.0 (0/839)
Pulmonic valve valvuloplasty 0.0 (0/839)
SD, Standard deviation; NYHA, New York Heart Association; STS, Society of
Thoracic Surgeons; CABG, coronary artery bypass grafting; ICD, implantable cardi-
overter defibrillator.
APPENDIX E2. Cardiovascular comorbidities (as-treated INTUITY,
n ¼ 839)
Condition % (n/N)
Aortic stenosis 100 (839/839)
Mitral insufficiency 95.9 (805/839)
Tricuspid insufficiency 95.9 (805/839)
Systemic hypertension 86.4 (725/839)
Cardiac rhythm abnormalities/conduction disturbance 66.6 (559/839)
Coronary artery disease 53.8 (451/839)
Congestive heart failure 48.8 (409/838)
Pulmonary hypertension 40.0 (334/836)
Carotid artery disease 28.0 (235/839)
Peripheral artery/vascular disease 16.8 (141/839)
Myocardial infarction 9.9 (83/839)
Transient ischemic attack 7.0 (59/839)
Cerebrovascular accident 5.5 (46/839)
Cardiomyopathy 5.1 (43/839)
Rheumatic fever 4.5 (38/838)
Mitral stenosis 2.3 (19/839)
Tricuspid stenosis 1.0 (8/838)
Endocarditis 0.2 (2/839)
Myocarditis 0.1 (1/839)
APPENDIX E3. Noncardiovascular risk factors (as-treated
INTUITY, n ¼ 839)
Evolving Technology Barnhart et al
E
TCondition % (n/N)
Smoking 58.0 (486/838)
Current smoker 6.1 (51/838)
Previous smoker 51.9 (435/838)
Musculoskeletal dysfunction 52.2 (438/839)
Obesity (BMI 30) 46.7 (392/839)
Diabetes 33.1 (278/839)
Type 1 1.9 (16/837)
Type 2 31.1 (260/837)
Cancer 30.0 (252/839)
Chronic obstructive
pulmonary disease
15.5 (130/839)
Renal failure/insufficiency 11.6 (97/839)
Blood diatheses 6.8 (57/839)
Immunosuppression 6.4 (54/839)
Liver disease 3.9 (33/839)
Calcium metabolic disorder 0.6 (5/839)
BMI, Body mass index.
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APPENDIX E4. Aortic crossclamp time for enrolled patients (intent to treat)
Surgical approach
Full sternotomy
n mean ± SD
median (min, max)
Mini upper sternotomy
n mean ± SD
median (min, max)
Right thoracotomy
n mean ± SD
median (min, max)
All subjects
n mean ± SD
median (min, max)
Isolated AVR 221
49.3  26.9
44.0 (11.0, 268.0)
263
62.3  25.6
55.0 (23.0, 188.0)
64
66.4  24.7
60.0 (36.0, 174.0)
548
57.5  26.9
52.0 (11.0, 268.0)
AVR þ CABG 215
87.1  36.2
84.0 (26.0, 228.0)
3
79.0  21.0
79.0 (58.0, 100.0)
N/A 218
86.9  36.0
83.5 (26.0, 228.0)
AVR þ other 52
76.5  60.7
63.0 (28.0, 455.0)
25
78.0  34.6
77.0 (27.0, 188.0)
7
94.6  83.8
70.0 (43.0, 282.0)
84
78.5  56.1
64.0 (27.0, 455.0)
All subjects 522
71.2  41.2
61.0 (11.0, 455.0)
291
63.9  26.7
57.0 (23.0, 188.0)
72
70.9  37.5
61.5 (36.0, 282.0)
885*
68.8  36.9
60.0 (11.0, 455.0)
SD, Standard deviation; AVR, aortic valve replacement; CABG, coronary artery bypass grafting. *Missing data for 4 patients.
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Surgical group n, mean ± SD STS value P value
Isolated AVR, full sternotomy 222, 69.2  34.7 04.23 <.001
Isolated AVR, MIS 327, 84.6  33.5 111.44 <.001
AVR þ CABG 1 graft(s) 89, 87.1  34.2 125.95 <.001
AVR þ CABG 2 graft(s) 76, 113.3  38.4 144.95 <.001
AVR þ CABG 3 graft(s) 38, 140.6  44.0 163.60 .003
AVR þ CABG 4þ graft(s) 7, 171.0  44.4 180.49 .592
P values were calculated with 1-sample t-tests. SD, Standard deviation; STS, Society
of Thoracic Surgeons; AVR, aortic valve replacement; MIS, minimally invasive sur-
gery; CABG, coronary artery bypass grafting. *Society of Thoracic Surgeons data-
base for the period of July 2011 to December 2012.
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T000 TRANSFORM (Multicenter Experience With Rapid Deployment Edwards
INTUITY Valve System for Aortic Valve Replacement) US clinical trial:
Performance of a rapid deployment aortic valve
Glenn R. Barnhart, MD, Kevin D. Accola, MD, Eugene A. Grossi, MD, Y. Joseph Woo, MD,
Mubashir A. Mumtaz, MD, Joseph F. Sabik, MD, Frank N. Slachman, MD, Himanshu J. Patel, MD,
Michael A. Borger, MD, PhD, H. Edward Garrett, Jr, MD, Evelio Rodriguez, MD, Patrick M.
McCarthy, MD, William H. Ryan, MD, Francis G. Duhay, MD, MBA, Michael J. Mack, MD, and
W. Randolph Chitwood, Jr, MD, on behalf of the TRANSFORM Trial Investigators, Seattle, Wash;
Orlando, Fla; New York, NY; Palo Alto, Sacramento, and Irvine, Calif; Harrisburg, Pa; Cleveland,
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INTUITY eliminates complete concentric annular suturing providing an option for rapid surgical
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